Compliance Rate
Compliance Rate
42.86%
Compliant submissions
3
Incompliant submissions
4
Total trials
7
My Organizations' Clinical Trials
Showing 1550 of 2008 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 08/02/13
Due: 08/02/14
Phase: N/A
Priority: Normal
Start: 04/01/22
End: 04/02/22
Due: 04/02/23
Phase: N/A
Priority: Normal
Start: 06/30/02
End: 07/31/05
Due: 07/31/06
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 04/30/18
Due: 04/30/19
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 03/17/17
End: 07/18/18
Due: 07/18/19
Phase: N/A
Priority: Normal
Start: 04/17/17
End: 12/14/18
Due: 12/14/19
Phase: N/A
Priority: Normal
Start: 08/08/23
End: 12/12/23
Due: 12/12/24
Phase: N/A
Priority: Normal
Start: 03/23/22
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 03/26/21
End: 01/06/22
Due: 01/06/23
Phase: N/A
Priority: Normal
Start: 10/12/18
End: 03/30/20
Due: 03/30/21
Phase: N/A
Priority: Normal
Start: 04/30/15
End: 05/15/17
Due: 05/15/18
Phase: N/A
Priority: Normal
Start: 01/06/25
End: 06/01/27
Due: 06/01/28
Phase: N/A
Priority: Normal
Start: 01/14/18
End: 09/30/21
Due: 09/30/22
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Phase: N/A
Priority: Normal
Start: 06/29/23
End: 08/30/25
Due: 08/30/26
Phase: N/A
Priority: Normal
Start: 01/05/17
End: 03/17/17
Due: 03/17/18
Phase: N/A
Priority: Normal
Start: 01/12/09
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 11/30/12
End: 11/30/14
Due: 11/30/15
Phase: N/A
Priority: Normal
Start: 10/08/19
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 01/10/19
End: 01/31/24
Due: 01/31/25
Phase: N/A
Priority: Normal
Start: 08/31/06
End: 08/31/11
Due: 08/31/12
Phase: N/A
Priority: Normal
Start: -
End: 03/31/05
Due: 03/31/06
Phase: N/A
Priority: Normal
Start: 01/31/26
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 08/31/16
Due: 08/31/17
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 10/30/28
Due: 10/30/29